Though epigenetic modifiers, such as DNMT3A, TET2, ASXL1, and IDH1/2, mutations were relatively rare in APL, they conferred APL one poor prognosis characterized by short overall survival duration and disease-free survival duration [17]. This evidence concerns the gene ASXL1 and acute promyelocytic leukemia.